These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 38219684)

  • 1. Portable Nanopore sequencing solution for next-generation HIV drug resistance testing.
    Park SY; Faraci G; Ganesh K; Dubé MP; Lee HY
    J Clin Virol; 2024 Apr; 171():105639. PubMed ID: 38219684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Absence of Integrase Strand Transfer Inhibitor Associated Resistance in Antiretroviral Therapy Naïve and Experienced Individuals from Western India.
    Karade S; Sen S; Sashindran VK
    AIDS Res Hum Retroviruses; 2019 Jun; 35(6):567-571. PubMed ID: 30793915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Full-spectrum HIV drug resistance mutation detection by high-resolution complete pol gene sequencing.
    Faraci G; Park SY; Dubé MP; Lee HY
    J Clin Virol; 2023 Jul; 164():105491. PubMed ID: 37182384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protease and gag diversity and drug resistance mutations among treatment-naive Mexican people living with HIV.
    Climaco-Arvizu S; Flores-López V; González-Torres C; Gaytán-Cervantes FJ; Hernández-García MC; Zárate-Segura PB; Chávez-Torres M; Tesoro-Cruz E; Pinto-Cardoso SM; Bekker-Méndez VC
    BMC Infect Dis; 2022 May; 22(1):447. PubMed ID: 35538426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A viral genome wide association study and genotypic resistance testing in patients failing first line antiretroviral therapy in the first large countrywide Ethiopian HIV cohort.
    Telele NF; Kalu AW; Gebre-Selassie S; Fekade D; Marrone G; Grossmann S; Neogi U; Tegbaru B; Sönnerborg A
    BMC Infect Dis; 2019 Jul; 19(1):569. PubMed ID: 31262272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Altered viral fitness and drug susceptibility in HIV-1 carrying mutations that confer resistance to nonnucleoside reverse transcriptase and integrase strand transfer inhibitors.
    Hu Z; Kuritzkes DR
    J Virol; 2014 Aug; 88(16):9268-76. PubMed ID: 24899199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary resistance against integrase strand transfer inhibitors in integrase strand transfer inhibitor-naive patients failing first- and second-line ART in Tanzania.
    Henerico S; Lyimo E; Makubi AN; Magesa D; Desderius B; Mueller A; Changalucha J; Kalluvya SE; Van Zyl G; Preiser W; Mshana SE; Kasang C
    J Antimicrob Chemother; 2022 Oct; 77(11):3138-3143. PubMed ID: 36101479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence and analysis of acquired and transmitted integrase strand transfer inhibitor-associated HIV-1 drug resistance in Chongqing, China.
    Zhang H; Wu P; Li J; Li M
    Virulence; 2023 Dec; 14(1):2278254. PubMed ID: 37941373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trends in HIV-1 Drug Resistance Mutations from a U.S. Reference Laboratory from 2006 to 2017.
    Kagan RM; Dunn KJ; Snell GP; Nettles RE; Kaufman HW
    AIDS Res Hum Retroviruses; 2019 Aug; 35(8):698-709. PubMed ID: 31169022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of resistance to integrase inhibitors among antiretroviral-naive subjects with primary HIV-1 infection, 2007-2013.
    Stekler JD; McKernan J; Milne R; Tapia KA; Mykhalchenko K; Holte S; Maenza J; Stevens CE; Buskin SE; Mullins JI; Frenkel LM; Collier AC
    Antivir Ther; 2015; 20(1):77-80. PubMed ID: 24831260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic diversity and antiretroviral resistance-associated mutation profile of treated and naive HIV-1 infected patients from the Northwest and Southwest regions of Cameroon.
    Meriki HD; Tufon KA; Anong DN; Atanga PN; Anyangwe IA; Cho-Ngwa F; Nkuo-Akenji T
    PLoS One; 2019; 14(11):e0225575. PubMed ID: 31751428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transmitted Drug Resistance to Integrase-Based First-Line Human Immunodeficiency Virus Antiretroviral Regimens in Mediterranean Europe.
    de Salazar A; Viñuela L; Fuentes A; Teyssou E; Charpentier C; Lambert-Niclot S; Serrano-Conde E; Pingarilho M; Fabeni L; De Monte A; Stefic K; Perno CF; Aguilera A; Falces I; Delgado R; Fernandes S; Diogo I; Gomes P; Paraskevis D; Santoro MM; Ceccherini-Silberstein F; Marcelin AG; Garcia F
    Clin Infect Dis; 2023 May; 76(9):1628-1635. PubMed ID: 36571282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cross-clade simultaneous HIV drug resistance genotyping for reverse transcriptase, protease, and integrase inhibitor mutations by Illumina MiSeq.
    Dudley DM; Bailey AL; Mehta SH; Hughes AL; Kirk GD; Westergaard RP; O'Connor DH
    Retrovirology; 2014 Dec; 11():122. PubMed ID: 25533166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Added Value of Next Generation over Sanger Sequencing in Kenyan Youth with Extensive HIV-1 Drug Resistance.
    Novitsky V; Nyandiko W; Vreeman R; DeLong AK; Manne A; Scanlon M; Ngeresa A; Aluoch J; Sang F; Ashimosi C; Jepkemboi E; Orido M; Hogan JW; Kantor R;
    Microbiol Spectr; 2022 Dec; 10(6):e0345422. PubMed ID: 36445146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV-1 drug resistance mutations detection and HIV-1 subtype G report by using next-generation sequencing platform.
    Gholami M; Rouzbahani N; Samiee S; Tayeri K; Ghorban K; Dehkharghani AD; Gholami AA; Moshiri F; Sattari A; Dadmanesh M; Mohraz M
    Microb Pathog; 2020 Sep; 146():104221. PubMed ID: 32360523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary resistance to integrase strand transfer inhibitors in Spain using ultrasensitive HIV-1 genotyping.
    Casadellà M; Santos JR; Noguera-Julian M; Micán-Rivera R; Domingo P; Antela A; Portilla J; Sanz J; Montero-Alonso M; Navarro J; Masiá M; Valcarce-Pardeiro N; Ocampo A; Pérez-Martínez L; Pasquau J; Vivancos MJ; Imaz A; Carmona-Oyaga P; Muñoz-Medina L; Villar-García J; Barrufet P; Paredes R;
    J Antimicrob Chemother; 2020 Dec; 75(12):3517-3524. PubMed ID: 32929472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistance.
    Tzou PL; Rhee SY; Descamps D; Clutter DS; Hare B; Mor O; Grude M; Parkin N; Jordan MR; Bertagnolio S; Schapiro JM; Harrigan PR; Geretti AM; Marcelin AG; Shafer RW;
    J Antimicrob Chemother; 2020 Jan; 75(1):170-182. PubMed ID: 31617907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends in HIV-1 pretreatment drug resistance and HIV-1 variant dynamics among antiretroviral therapy-naive Ethiopians from 2003 to 2018: a pooled sequence analysis.
    Kiros M; Biset S; Gebremariam B; Yalew GT; Abegaz WE; Geteneh A
    Virol J; 2023 Oct; 20(1):243. PubMed ID: 37880705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence and determinants of resistance mutations in HIV-1-infected patients exposed to integrase inhibitors in a large Italian cohort.
    Modica S; Rossetti B; Lombardi F; Lagi F; Maffeo M; D'Autilia R; Pecorari M; Vicenti I; Bruzzone B; Magnani G; Paolucci S; Francisci D; Penco G; Sacchini D; Zazzi M; De Luca A; Di Biagio A
    HIV Med; 2019 Feb; 20(2):137-146. PubMed ID: 30461149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary resistance to integrase strand-transfer inhibitors in Europe.
    Casadellà M; van Ham PM; Noguera-Julian M; van Kessel A; Pou C; Hofstra LM; Santos JR; Garcia F; Struck D; Alexiev I; Bakken Kran AM; Hoepelman AI; Kostrikis LG; Somogyi S; Liitsola K; Linka M; Nielsen C; Otelea D; Paraskevis D; Poljak M; Puchhammer-Stöckl E; Staneková D; Stanojevic M; Van Laethem K; Zidovec Lepej S; Clotet B; Boucher CA; Paredes R; Wensing AM;
    J Antimicrob Chemother; 2015 Oct; 70(10):2885-8. PubMed ID: 26188038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.